CHAP# 1. EXECUTIVE SUMMARY
CHAP# 2. MARKET OVERVIEW
# 2.1. WHAT ARE CGMS?
# 2.2. VALUE CHAIN ANALYSIS OF THE ROLE OF SUPPLER, MANUFACTURER, AND END USER IN THE CGMS MARKET
# 2.2.1. SUPPLIERS ENABLING FINANCIALLY WEAK PLAYERS
# 2.2.2. MANUFACTURERS FACING REGULATIONS AND OPERATIONAL COST ISSUES
# 2.2.3. PEDIATRICS AND HOSPITALS WILL LEAD THE FUTURE MARKET GROWTH
# 2.3. KEY BUYING CRITERIA
# 2.3.1. CONVENIENCE FACTOR
# 2.3.2. PRICE IS THE KEY CONCERN
# 2.3.3. IMPROVED ACCURACY LEADS TO EASIER REGULATION NORMS
# 2.3.4. COLLABORATION OF THE TWO MAIN MANUFACTURERS
# 2.3.5. DEVELOPMENT OF DURABLE SENSORS
# 2.3.6. DEVELOPMENT OF APD
# 2.3.7. FOCUS ON DEVELOPING ASIAN MARKETS
# 2.3.8. PARTNERSHIPS AND COLLABORATIONS – THE WINNING STRATEGIES
# 2.3.9. INNOVATION IMPORTANT FOR NEW ENTRANTS
CHAP# 3. MARKET DETERMINANTS
# 3.1. CGMS MARKET MOTIVATORS
# 3.1.1. DIABETES POPULATION RISE LEADS TO LARGER MARKET OPPORTUNITY
# 3.1.2. RISE IN THE GLOBAL HEALTH EXPENDITURE AND EMERGING ASIAN MARKET
# 3.1.3. INCREASED R&D FUNDING FOR FASTER APPROVALS AND DEVELOPMENT OF APD
# 3.1.4. INSULIN PUMP MANUFACTURERS WILLING TO INTEGRATE CGMS AND INSULIN PUMP TECHNOLOGY
# 3.1.5. PRIVATE INSURERS INCREASING CGMS AFFORDABILITY
# 3.1.6. NEW TECHNOLOGY CAN BRING DOWN PRICES
# 3.2. RESTRAINTS
# 3.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
# 3.2.2. ESTABLISHED SMBG DEVICE MANUFACTURERS RESTRAINING CGMS GROWTH
# 3.2.3. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
# 3.3. OPPORTUNITIES
# 3.3.1. GROWING DIABETIC POPULATION
# 3.3.2. EMERGENCE OF NEW SEGMENT - PEDIATRICS
# 3.3.3. CASE STUDY ON PEDIATRICS USE
# 3.3.4. DEVELOPMENT OF ARTIFICIAL PANCREAS
# 3.4. CHALLENGES IN CGMS MARKET
# 3.4.1. HIGH PRICE
# 3.4.2. UNMET DIABETIC NEEDS
# 3.4.3. NO GOVERNMENT AID MAKES IT DIFFICULT FOR THE CONSUMER
CHAP# 4. SECTOR ANALYSIS: DIABETES CARE
CHAP# 5. CGMS MARKET BY DEVICES
# 5.1. LONG LASTING SENSORS: THE NEED OF THE HOUR
# 5.1.1. FACTORS INFLUENCING CGM SENSOR DEVELOPMENT
# 5.2. TRANSMITTERS AND RECEIVERS - THE STANDALONE SYSTEM
# 5.2.1. PRICE THE MAJOR RESTRAINT FOR TRANSMITTERS AND RECIEVERS
# 5.3. INSULIN PUMPS HOLD THE FUTURE
# 5.3.1. INNOVATION AND COLLABORATION THE MAINSTAY FOR INSULIN PUMPS
CHAP# 6. BY APPLICATION
# 6.1. PROFESSIONAL CGMS (USED BY HEALTHCARE PROFESSIONALS)
# 6.1.1. PROFESSIONAL CGMS TYPES
# 6.1.2. CASE STUDY ON USE OF CGMS IN HOSPITAL SETTINGS
# 6.1.3. CASE STUDY 2:MEDTRONIC REAL TIME CGMS IN RURAL SETTINGS
# 6.1.4. PERSONAL CGMS SEGMENTED ON THE BASIS OF AGE GROUPS
CHAP# 7. COMPETITIVE INTELLIGENCE
# 7.1. KEY STRATEGIES TO HELP CGMS MARKET DRIVE ACCEPTANCE
# 7.1.1. INNOVATION THE KEY INDUSTRY TO OVERCOME COMPETITION
# 7.1.2. TECHNOLOGY LEVERAGING - KEY FOCUS OF PARTNERSHIPS AMONG INDUSTRY PLAYERS
# 7.1.2.1. KEY OBJECTIVE OF PARTNERSHIPS AND AGREEMENTS IN THE CGMS MARKET
# 7.1.2.2. MAJOR AGREEMENTS SIGNED BY CGMS MANUFACTURERS SINCE 2007
# 7.1.3. PRODUCT LAUNCH - A MAKE OR BREAK MARKETING STRATEGY
# 7.1.3.1. RECENT PRODUCT LAUNCHES
# 7.1.4. ACQUISITIONS STILL REMAIN NICHE IN THE CGMS MARKET
CHAP# 8. MARKET SHARE ANALYSIS
# 8.1. KEY COMPANY ANALYSIS
# 8.1.1. DEXCOM
# 8.1.2. MEDTRONIC
# 8.1.3. ABBOTT DIABETES CARE
# 8.1.4. MARKET SHARE
# 8.1.5. CONCLUSION
CHAP# 9. GEOGRAPHICAL ANALYSIS
# 9.1. NORTH AMERICA
# 9.1.1. UNITED STATES OF AMERICA
# 9.1.1.1. A DEVELOPED ECONOMY A MAJOR BUSINESS DRIVER
# 9.1.1.2. AWARENESS IS THE KEY TO CGMS ADOPTION
# 9.1.1.3. MEDICARE AND REIMBURSEMENTS ARE THE FUTURE DRIVERS
# 9.1.1.4. HIGH NUMBER OF T1D
# 9.1.1.5. REGULATIONS OBSTRUCTING MARKET EXPANSION
# 9.1.1.5.1. US FDA guidelines for the development of artificial pancreas
# 9.1.1.5.1.1. Primary components of an APD
# 9.1.1.5.1.2. Secondary component
# 9.1.1.6. KEY MARKET PLAYERS IN THE US
# 9.2. CANADA
# 9.2.1. REGULATIONS IN CANADA
# 9.3. EUROPE 87
# 9.3.1. EUROPEAN UNION (EU)
# 9.3.1.1. THE UK
# 9.3.1.1.1. Regulations in the UK
# 9.3.1.1.2. Key companies in the UK
# 9.3.1.2. FRANCE
# 9.3.1.3. GERMANY
# 9.3.1.4. CGMS BUSINESS IN THE EU
# 9.4. ASIA PACIFIC
# 9.4.1. CHINA
# 9.4.1.1. REGULATIONS IN CHINA
# 9.4.2. INDIA
# 9.4.2.1. REGULATION IN INDIA
# 9.4.2.2. CGMS IN INDIA
# 9.4.3. AUSTRALIA
# 9.4.3.1.1. Regulations in Australia
# 9.5. LATIN AMERICA
# 9.5.1. FACTSHEET OF DIABETES STATISTICS IN LATIN AMERICA
# 9.5.1.1. BRAZIL
# 9.5.1.2. ARGENTINA
# 9.5.1.3. MEXICO
# 9.5.2. REST OF THE WORLD
# 9.5.2.1. MIDDLE-EAST AND NORTH AFRICA
# 9.5.2.2. AFRICA
CHAP# 10. CORPORATE PROFILE: BENCHMARK STUDY
# 10.1. MEDTRONIC INC.
# 10.1.1. BUSINESS PROFILE
# 10.1.2. PRODUCT PORTFOLIO
# 10.1.3. REVENUE ANALYSIS
# 10.1.4. STRATEGIC INPUTS
# 10.2. DEXCOM
# 10.2.1. LOCATION
# 10.2.2. BUSINESS PROFILE
# 10.2.3. PRODUCT PORTFOLIO
# 10.2.4. REVENUE ANALYSIS
# 10.2.5. STRATEGIC INPUTS
# 10.3. ABBOTT
# 10.3.1. LOCATIONS
# 10.3.2. BUSINESS PROFILE
# 10.3.3. PRODUCT PORTFOLIO
# 10.3.4. REVENUE ANALYSIS
# 10.3.5. STRATEGIC INPUTS
# 10.4. JOHNSON AND JOHNSON (J&J) (ANIMAS CORP)
# 10.4.1. LOCATIONS
# 10.4.2. BUSINESS PORTFOLIO
# 10.4.3. PRODUCT PORTFOLIO
# 10.4.4. REVENUE ANALYSIS
# 10.5. INSULET CORP
# 10.5.1. GEOGRAPHY
# 10.5.2. BUSINESS PORTFOLIO
# 10.5.3. PRODUCT PORTFOLIO
# 10.5.4. REVENUE ANALYSIS
# 10.5.5. STRATEGIC INPUTS
# 10.6. TANDEM DIABETES
# 10.6.1. BUSINESS PORTFOLIO
# 10.6.2. REVENUE ANALYSIS
# 10.7. ECHO THERAPEUTICS
# 10.7.1. BUSINESS PORTFOLIO
# 10.7.2. PRODUCT PORTFOLIO
# 10.7.3. REVENUE ANALYSIS
